Why Sarcopenic Obesity Diagnosis Depends on Which Definition You Use

Ask three different research teams to diagnose the same group of people for sarcopenic obesity, using three accepted, published methods, and you can get three meaningfully different answers about who actually has it. This is not a hypothetical. It is what has repeatedly happened when researchers apply multiple diagnostic frameworks to the same dataset. For a condition that this site covers largely through its biology, its causes, and its prevention, it is worth pausing on a more basic and arguably more consequential problem: researchers, and increasingly clinicians, still do not agree on how to measure it. That disagreement is not a minor technicality. It changes who gets counted, who gets flagged for early intervention, and, for a screening project like the one this site supports among young Omani adults, what a "positive" result even means.

What a Diagnosis Actually Requires

Sarcopenic obesity is defined, in principle, as the coexistence of two things in one body: excess adiposity and low skeletal muscle mass or function. That definition sounds simple, but each half hides several possible measurements. Excess adiposity can be assessed through body mass index, waist circumference, percent body fat from a body composition scan, or visceral fat area from imaging. Low muscle mass or function can be assessed through appendicular lean mass adjusted for height or weight, handgrip strength, gait speed, or a short physical performance battery. Every one of those measurement choices has its own cutoff values, its own equipment requirements, and its own strengths and blind spots. A diagnostic framework is really a bundle of choices about which of these measurements to use and where to draw the line, and different expert groups have made different choices.

The 2022 Consensus, and What It Actually Proposes

In 2022, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) published a joint consensus statement in the journal Obesity Facts, authored by a 32 person international expert panel led by Lorenzo Donini and Rocco Barazzoni. It proposes a staged diagnostic algorithm. At risk individuals who screen positive for an elevated BMI or waist circumference, alongside risk factors or a validated questionnaire, should first have their skeletal muscle function assessed, typically through handgrip strength. Only if that screen is positive does the algorithm move to a full body composition assessment, confirming the coexistence of excess fat and low muscle mass. People who meet the criteria are then further classified as stage I, with no clinical complications, or stage II, where complications linked to the altered body composition are already present. The panel explicitly framed this as an attempt to end the inconsistency that had built up in the literature and encouraged prospective studies to validate it. What has happened since is instructive: rather than replacing the older methods, the new consensus has mostly been tested alongside them, and the comparisons have not been reassuring.

When Several Methods Are Pointed at the Same People

Two recent Chinese cohort studies illustrate the scale of the disagreement directly, because both applied multiple diagnostic methods to the exact same participants rather than comparing separate studies with separate populations. A 2022 study in Age and Ageing by Mo and colleagues examined 1,050 community dwelling older adults, combining the Asian Working Group for Sarcopenia 2019 (AWGS2019) sarcopenia criteria with four different obesity definitions: BMI, waist circumference, percent body fat, and visceral fat area. Depending only on which obesity measure was paired with the same sarcopenia criteria, the prevalence of sarcopenic obesity in this single population ranged from 0.1 percent to 7.9 percent, nearly an eightyfold spread. Statistical agreement between the four methods, measured with Cohen's kappa, ranged from essentially zero agreement (kappa of negative 0.002 between the BMI based method and the others) up to moderate agreement (kappa of 0.682 between the visceral fat area and waist circumference based methods).

A larger 2024 study in Frontiers in Public Health by Dong and colleagues, drawing on 4,155 participants from the West China Health and Aging Trend cohort, went a step further by also including the full 2022 ESPEN and EASO consensus criteria alongside four AWGS based combinations. Prevalence again varied considerably, from 0.63 percent using AWGS combined with BMI up to 7.22 percent using AWGS combined with waist circumference, with the ESPEN and EASO consensus method landing at 6.93 percent. The more striking finding was about agreement rather than prevalence. The ESPEN and EASO consensus, the newest and most internationally endorsed framework, had the poorest agreement with every other method tested, with kappa values between 0.06 and 0.32. Its best match was with the percent body fat based method, at a kappa of just 0.32, which by standard interpretation still only counts as fair agreement. The authors also found that which sex appeared to carry more risk flipped depending on the method: the ESPEN and EASO consensus and the percent body fat method found sarcopenic obesity more common in men, while the waist circumference and visceral fat area methods found it more common in women. Two methods, applied to the same people, could not even agree on which sex was more affected.

Why Body Fat Measures Disagree So Sharply

Part of the explanation is mechanical. BMI is a weight and height ratio that cannot distinguish fat from muscle, and both of the Chinese cohort studies found it had by far the lowest diagnostic sensitivity of any obesity measure, in one case flagging only a single participant out of over a thousand as obese enough to qualify. Waist circumference and visceral fat area, by contrast, are picking up central fat accumulation, which tends to be more common in women after menopause due to hormonal shifts in fat distribution, which is part of why those two methods flagged more women. Percent body fat from a body composition scan captures total adiposity regardless of location, which explains its closer relationship to the ESPEN and EASO consensus approach, since both are attempting to measure overall fat burden rather than central fat specifically. None of these methods is simply wrong. They are measuring genuinely different things that happen to overlap only partially, and a diagnosis of sarcopenic obesity built on any single one of them is really a diagnosis of "excess fat by this particular yardstick, combined with low muscle by this particular yardstick," not a single unambiguous biological fact.

Whose Body Sets the Cutoff

A separate, and for this project especially relevant, source of disagreement is where the muscle mass cutoff itself gets drawn, because that number is usually calculated from a specific reference population and then applied elsewhere. A 2025 study in Frontiers in Nutrition by Alhussain and colleagues measured appendicular lean mass adjusted for height squared (ALM/height²) in 387 healthy young Saudi women aged 18 to 25, using bioelectrical impedance analysis, specifically to establish a local reference range rather than importing one. The mean value in this healthy young reference group was 5.63 kg/m², and the cutoff for low muscle mass, defined as two standard deviations below that mean, worked out to 4.09 kg/m². Compare that to the cutoffs already in use internationally for women: 6.0 kg/m² under the revised European consensus (EWGSOP2), 5.67 kg/m² under the International Working Group on Sarcopenia, and 5.4 kg/m² under the Asian Working Group for Sarcopenia. Every one of those imported cutoffs sits well above the empirically measured normal range for young, healthy Saudi women in this study. Applied directly, they would flag a large share of genuinely healthy young Gulf women as having low muscle mass, simply because the reference population used to build the cutoff was not drawn from a similar body type, activity pattern, or genetic background. The study's authors explicitly recommend against relying on imported values for exactly this reason, and argue instead for region specific reference values built from healthy young adults in the population being screened.

Why This Matters More for Young Adults, Not Less

Almost all of the large diagnostic agreement studies available, including both Chinese cohorts discussed above, were conducted in middle aged or older adults, often specifically because sarcopenia was historically framed as an aging related condition. That leaves a real gap for young adults, where body composition, activity patterns, and the interaction between obesity and muscle mass can look quite different from a 70 year old. The Saudi reference value study is one of the few pieces of evidence built specifically from a young adult Gulf population, and its central finding, that internationally imported cutoffs can sit meaningfully outside the locally measured normal range, is exactly the kind of gap this site's affiliated research project is trying to close through metabolomic and genetic screening of young Omani adults. A screening tool validated on 70 year old Chinese or European bodies is not automatically valid for a 22 year old Omani body, and until region specific reference data exists, any single prevalence estimate for sarcopenic obesity in young Gulf adults should be read as provisional. For more on how body composition assessment works in practice, see our page on diagnostic criteria and how they're assessed, and for the broader case that a normal looking BMI can hide this condition entirely, see our earlier piece on why your BMI might be lying to you in your 20s.

Limitations and What Remains Uncertain

Several caveats apply to all of this. The two Chinese cohort studies used cross-sectional designs, meaning they can compare how methods agree with each other at one point in time but cannot say which method best predicts real health outcomes like falls, frailty, or mortality over years, which is ultimately the more important question. Kappa statistics are also sensitive to how common a condition is in the sample being studied, so agreement figures from one population do not automatically transfer to another. The Saudi reference value study, while methodologically useful as a model for what region specific data can reveal, measured only muscle mass and not muscle strength or physical performance, and drew its sample from a single university site rather than a broad, representative cross section of the population. No comparable published reference dataset yet exists for young adults in Oman specifically, which is precisely the evidence gap this site's affiliated research aims to help fill rather than a settled question this post can resolve.

Connecting Back to Sarcopenic Obesity

The practical upshot is that "sarcopenic obesity prevalence" is not a single, stable number waiting to be discovered. It is a number that shifts substantially depending on which body fat measure, which muscle measure, and which population derived cutoff a given study or clinician chooses to use, and the disagreement between methods is largest, not smallest, when comparing the newest consensus framework against the older, simpler ones. For readers, the takeaway is not that diagnosis is meaningless, but that a single test result, especially one based on BMI alone, should be treated as a starting point for a conversation with a healthcare provider rather than a final verdict. For the field, and for research projects screening young adult populations that current tools were not built around, it is a reminder that better prevalence estimates depend on continuing to build reference data specific to the population being studied, our complete guide to sarcopenic obesity in young adults covers the broader diagnostic picture in more depth. This post is for general education and isn't medical advice. Speak with a healthcare provider about which assessment is appropriate for your individual situation.

References

• Obesity Facts (2022) — Donini, Busetto, Barazzoni et al.: Definition and Diagnostic Criteria for Sarcopenic Obesity, ESPEN and EASO Consensus Statement
• Age and Ageing (2022) — Mo et al.: Prevalence and diagnostic agreement of sarcopenic obesity with different definitions among Chinese community-dwelling older adults
• Frontiers in Public Health (2024) — Dong et al.: The diagnostic agreement of sarcopenic obesity with different definitions in Chinese community-dwelling middle-aged and older adults
• Frontiers in Nutrition (2025) — Alhussain et al.: Reference values for the appendicular lean muscle index in healthy young Saudi women, a nutritional perspective